Other
Post-Transplant Lymphoproliferative Disorder
2
Pipeline Programs↗
3
Active Trials↗
2
Companies Involved↗
Post-Transplant Lymphoproliferative Disorder is an early-stage landscape with 2 programs across 2 companies. The most active players are Roche, Bristol-Myers Squibb.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
3programs
Small molecule133%
Monoclonal antibody133%
Antibody–drug conjugate133%
Modality classified for 100% of 3 pipeline programs.
Analysis
Trial Status
9
clinical trials
Completed4 · 44%
Recruiting2 · 22%
Terminated1 · 11%
Withdrawn1 · 11%
Active, not recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Recruiting·—·Phase 2·NCT05786040·28 enrolled
A Phase I/II Study of Frontline Therapy With Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT06040320·12 enrolled
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02182986·944 enrolled
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Withdrawn·—·Phase 2·NCT03086395
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)